SCHEMBL677575

SCHEMBL677575

COc1cc2c(CCNC(C)=O)c(C)[nH]c2c(Cl)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 14/20 1.00
MTNR1B P49286 14/20 1.00
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
NQO2 P16083 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
CYP2C9 P11712 1/20 0.50
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
SLC6A4 P31645 1/20 0.50
CYP2C19 P33261 1/20 0.50
THPO P40225 1/20 0.50
HTR2B P41595 1/20 0.50
KMT2A Q03164 1/20 0.50
HIF1A Q16665 1/20 0.50
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7883115 0.89 MTNR1A (0.80) MTNR1AMTNR1BHSD17B10TP53NQO2
SCHEMBL7883051 0.87 MTNR1A (0.77) MTNR1AMTNR1BHSD17B10KDM4E
SCHEMBL7888564 0.84 MTNR1A (0.72) MTNR1AMTNR1BHSD17B10TP53NQO2
SCHEMBL11615487 0.83 MTNR1A (1.00) MTNR1AMTNR1BHSD17B10TP53NQO2
SCHEMBL8822711 0.81 MTNR1A (0.66) MTNR1AMTNR1BHSD17B10NQO2CYP1A2
SCHEMBL7893103 0.79 MTNR1A (0.69) MTNR1AMTNR1BHSD17B10NQO2CYP1A2
SCHEMBL10908623 0.79 MTNR1A (0.64) MTNR1AMTNR1BHSD17B10TP53CYP1A2
SCHEMBL18239788 0.78 MTNR1A (0.75) MTNR1AMTNR1BHSD17B10NQO2CYP1A2
SCHEMBL7894816 0.78 MTNR1A (0.80) MTNR1AMTNR1BHSD17B10TP53NQO2
SCHEMBL8822717 0.75 MTNR1A (0.58) MTNR1AMTNR1BNQO2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056897-B1 MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL BLUE MEDICAL DEVICES B V (NL) 2009-12-30 EP claimed
US-20090258053-A1 MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL BLUE MEDICAL DEEVICES BV (NL) 2009-10-15 US claimed
EP-2056897-A1 MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL Blue Medical Devices B.V. (NL) 2009-05-13 EP claimed
WO-2008023038-A1 MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL BLUE MEDICAL DEVICES BV (NL) 2008-02-28 WO claimed
EP-4706758-A2 METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2026-03-11 EP disclosed
US-20240325487-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2024-10-03 US disclosed
US-11813304-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2023-11-14 US disclosed
US-20230277523-A1 METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2023-09-07 US disclosed
EP-3884935-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2023-06-14 EP disclosed
CN-114404588-A Compounds and methods for inhibiting phosphate transport 阿德利克斯公司 2022-04-29 CN disclosed
CN-114340631-A Combination for reducing serum phosphate in a patient 阿德利克斯股份有限公司 2022-04-12 CN disclosed
EP-3972599-A1 COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT Ardelyx, Inc. (US) 2022-03-30 EP disclosed
US-6239162-B1 ADMINISTERING 5-METHOXYCARBONYLAMINO-N-ACETYLTRYPTAMINE; ANXIOLYTIC AGENTS; OBSESSIVE COMPULSIVE DISORDER ST. ELIZABETH'S MEDICAL CENTER 2001-05-29 US disclosed
EP-0549916-A2 Compounds useful as antiproliferative agents WHITBY RESEARCH, Inc. (US) 1993-07-07 EP disclosed
US-5151446-A Neurological disorders or cardiovascular disorders NORTHWESTERN UNIVERSITY (US) 1992-09-29 US disclosed
US-5071875-A Nervous system, psychological disorders; sleep cycle, skin dis coloration NORTHWESTERN UNIVERSITY (US) 1991-12-10 US disclosed
EP-0420064-A2 Substituted 2-amidotetralins as melatonin agonists and antagonists NORTHWESTERN UNIVERSITY (US) 1991-04-03 EP disclosed
EP-0375726-A4 MELATONIN ANALOGUES 1991-01-30 EP disclosed
EP-0375726-A1 MELATONIN ANALOGUES Whitby Research Incorporated (US) 1990-07-04 EP disclosed
WO-1989001472-A1 MELATONIN ANALOGUES NELSON RESEARCH & DEVELOPMENT CO. (US) 1989-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258053-A1 MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL MTNR1B, MTNR1A, MYLK MTNR1A 2/4885MTNR1B 1/4885HSD17B10 3987/4885
US-20240325487-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A3, SLC34A2, SLC34A1 MTNR1A 3262/4885MTNR1B 3128/4885HSD17B10 1801/4885
US-11813304-B2 Compounds and methods for inhibiting phosphate transport SLC34A3, SLC34A2, SLC34A1 MTNR1A 3262/4885MTNR1B 3128/4885HSD17B10 1801/4885
US-20230277523-A1 METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A3, SLC34A2, SLC34A1 MTNR1A 3825/4885MTNR1B 3664/4885HSD17B10 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.